JP Morgan Upgrades Ariad Pharmaceuticals (ARIA) to Overweight
More News related to ARIA
- ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- Morning Movers 11/09: EWBC, CVM, REV, CGEN, RSH Higher; CHDX, SRZ, GTN, RPRX, VSR Lower
- JP Morgan Upgrades Ariad Pharmaceuticals (ARIA) to Overweight
- ARIAD Pharma (ARIA) Posts Q3 Loss of 21c, Misses Views by 3c
- ARIAD Reports Third Quarter 2009 Development Progress and Financial Results
More News related to Trader Talk
- Netlist (NLST): A Short Squeeze or a New Tech Powerhouse?
- Hewlett-Packard (HPQ) Set To Deliver Already Telegraphed Q4 Results
- Bove Says BofA (BAC) Shareholders Want Lewis Back in CEO Spot
- Global Defense Technology (GTEC) IPO Trades Flat
- Archipelago Learning (ARCL) IPO Jumps Higher
JP Morgan upgrades Ariad Pharmaceuticals Inc. (Nasdaq: ARIA) Neutral to Overweight with a $6 price target.
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.
Related Categories
Trader TalkUpgrades
Stocks Mentioned
-0.03Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
